Oct 10, 2024
LSX Nordics 2024 Interview
At the LSX - partnering for Life Science eXecutives congress, Director of Immuno-Oncology & Preclinical Development, Stine Friis, shared Evaxion's recent achievements on large pharma deals and the promising data from our Phase 2 personalized cancer vaccine trial, highlighting the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets.
Credits: BioStock